Leucine-Rich, Glioma-Inactivated Protein 1 Antibody, IgG CBA-IFA and Contactin-Associated Protein-2 Antibody, IgG CBA-IFA with Reflex to Titers, Serum
Also known as: LGI1CASPR2
Use
This test aids in the diagnosis of disorders associated with antibodies to leucine-rich glioma inactivated 1 protein (LGI1) and contactin-associated protein 2 (CASPR2). These antibody disorders are rarely associated with tumors. LGI1 antibody disorders are linked with limbic encephalitis, hyponatremia, and myoclonic movements, while CASPR2 antibody disorders are associated with acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. The test is important for managing antibody-positive individuals undergoing immunotherapy or plasmapheresis.
Special Instructions
If either LGI1 or CASPR2 antibody IgG is positive, subsequent titer testing will be added, resulting in additional charges.
Limitations
The test has been developed by ARUP Laboratories, and its performance characteristics were determined by them. It has not received clearance or approval from the US Food and Drug Administration but is performed in a CLIA certified lab for clinical purposes. Results should be interpreted in conjunction with the patient's clinical history and other laboratory findings.
New York Approved
Methodology
Cell-based / Cytometry (Other)
Biomarkers
LOINC Codes
- 82979-6
- 82978-8
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.2 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum from cells within 2 hours of collection.
Causes for Rejection
CSF or plasma. Contaminated, hemolyzed, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year (avoid repeated freeze/thaw cycles) |